Subscribe

Study Summaries

SOLO-3: Olaparib vs. Chemotherapy in PSROC

Olaparib significantly improved PFS and ORR over nonplatinum chemotherapy, though no OS benefit was observed in the overall population. In patients with ≥3 prior therapies, chemotherapy had more favorable OS.

NRG-GY023: Durvalumab, Olaparib, and Cediranib vs Chemotherapy in Platinum-Resistant Ovarian Cancer with Prior Bevacizumab

The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.

ARIEL 4

PALETTE: Pazopanib for Metastatic Soft-Tissue Sarcoma

PALEO Trial: Palbociclib + Letrozole in Endometrial Cancer

The combination of palbociclib and letrozole significantly improved PFS compared to placebo with letrozole. However, it was associated with higher hematologic toxicities, particularly neutropenia.

Fulvestrant + Abemaciclib

The combination of abemaciclib and fulvestrant shows promising efficacy and manageable toxicity in HR-positive advanced or recurrent endometrial cancer, especially in CN-L/NSMP tumors

LEAP-001: Lenvatinib plus Pembrolizumab vs. Chemotherapy as First-Line Therapy for Advanced Endometrial Cancer

First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable. dMMR exploratory analysis shows promise in this subgroup.

CHIPOR: Secondary Debulking and HIPEC in Platinum-Sensitive Recurrent Ovarian Cancer

HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer

PAOLA-1 (2023 Update): Final Overall Survival Results — Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer

Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.

KEYNOTE-B21: Pembrolizumab Plus Adjuvant Chemotherapy in High-Risk Endometrial Cancer

Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population